ClinicalTrials.gg
CompletedNCT05170737AEF0217-101Updated Feb 1, 2024

AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.

A Phase 1 interventional study of AEF0217 and Placebo in Safety, Tolerability, Pharmacokinetics of AEF0217, sponsored by Aelis Farma. Completed at 1 site in Spain. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Aelis Farma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This trial is divided in 3 parts: FIH-SAD (Single Ascending Doses), FIH-MAD (Multiple Ascending Doses) and FIH-FE (Food effects). FIH-SAD will start first. The start of FIH-MAD will await the results of at least three cohorts from the FIHSAD study before initiated. The starting dose of the FIH-MAD will have been shown to be well tolerated and one dose level lower than the highest dose for which safety, tolerability and pharmacokinetic (PK) data are available. FIH-FE will be the last to start after the completion of FIH-SAD and conducted in parallel with parts of FIH-MAD.

02

Conditions studied

  • Safety, Tolerability, Pharmacokinetics of AEF0217
03

In context

Lead sponsor

Aelis Farma is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects: As the effect of the study drug on sperm is still unknown, male subjects should refrain from donating sperm or plan a pregnancy with their partner throughout the study and until 90 days after the trial and must report immediately to the study doctor if its partner becomes pregnant during the trial and during 90 days after the trial. The male subject will have to use double-barrier methods: male condoms and spermicide.
  • Healthy female subjects of non-: females may be accepted if they are documented to be surgically sterile i.e., hysterectomy, tubal ligation or with a negative pregnancy test (Not applicable for FIH-FE part III as it includes male only)
  • Age ≥ 18 and ≤ 55 years.
  • Weight ≥ 50 kg and ≤ 100 kg.
  • (BMI) ≥ 18 and ≤ 30.
  • Negative serum pregnancy test (women only)
  • Non-smoking.
  • No history of or ongoing diseases or conditions.
  • No clinically relevant findings in physical examination, vital signs (blood pressure, heart rate and body temperature), and safety laboratory parameters that should be within normal ranges or considered as non-clinically relevant by the investigator.
  • Negative covid19 PCR test within 72h before admission
  • Able/willing to accept restrictions regarding diet, physical exercise, and consumption of alcohol and/or xanthine containing items when out of CRU.
  • Able to read Spanish and adhere to study requirements.
  • Not under any administrative or legal supervision.
  • Signed prior to any study-mandated procedure.

Exclusion criteria

Exclusion Criteria:

  • Women of
  • Life-time substance use disorders (SUD) according to the (DSM-5).
  • Recreational use of drugs of abuse within the last month prior to study drug administration.
  • Positive blood or urine test for drugs of abuse or alcohol breath test prior to study drug administration.
  • Life-time history of bipolar disorders, psychosis or suicidal attempts assessed by the Dual Diagnosis Screening Instrument (DDSI).
  • History of anxiety or depression not completely recovered within 12 months prior to study drug administration, as assessed by the DDSI.
  • Lifetime history of deliberate self-harm due to suicidal ideation or suicidal ideation prior to study drug administration, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • cognitive impairment preventing the administration of the psychometric tests
  • Any other clinically relevant disease or condition that in the judgment of the investigator might interfere with the subject's ability to comply with study procedures or requirements and/or bias the interpretation of the study results and/or jeopardize the subject's safety.
  • Ongoing gastrointestinal diseases or history of gastrointestinal surgery affecting absorption
  • Subjects with a clinically significant disease within one month prior to study drug administration.
  • Any clinically relevant findings in physical examination, vital signs, and safety laboratory parameters.
  • Positive hepatitis or test.
  • Positive Covid19 PCR test within 72h before admission (Day -1) to the research facility
  • Have abnormal screening values for the hormones: cortisol, testosterone, estradiol and progesterone relative to their reproductive status.
  • Known to any drug (in particular steroids) or drug .
  • Use of drugs known to induce or inhibit hepatic drug metabolism within one month prior to study administration or during the study and use of citrus juice during the study.
  • Any prescription or over-the-counter (OTC) product including herbal, homeopathic, vitamins, minerals and nutritional supplements and in particular any parenteral or topical product containing steroids, within 2 weeks (or more considering the elimination half-life of the product) prior to study drug administration
  • Donation of blood or plasma within one month prior to study drug administration or transfusion of blood or plasma for medical/surgical reasons or intention to donate blood or plasma within one month after study drug administration.
  • History of inadequate venous access and/or experience of difficulty donating blood.
  • Not able/not willing to accept restrictions regarding diet, physical exercise, and consumption of alcohol and/or xanthine containing items when out of CRU.
  • Subject included in a clinical study within 3 months prior to study drug administration.
  • Subject already included in other parts of this study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    PART I: SINGLE ASCENDING DOSE (FIH-SAD)

    Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-group, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in single ascending doses.

    Drug: AEF0217 · Drug: Placebo

  • Experimental
    PART II: MULTIPLE ASCENDING DOSES (FIH-MAD)

    Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-groups, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in multiple ascending doses.

    Drug: AEF0217 · Drug: Placebo

  • Experimental
    PART III: FOOD EFFECT (FIH-FE)

    Prospective, open-label single dose, two-condition (fed versus fasting), two sequences, crossover phase I investigation to assess the effects of food on the bioavailability of AEF0217.

    Drug: AEF0217

Interventions

  • PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort. PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort. PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.

    Also known as: 3ß-benzyloxy-17α-methyl-pregn-5-en-20-one

  • DrugPlacebo

    PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort. PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent AEs and SAEs as assessed by vital signs

    Evaluation by grade intensity and by evaluating changes from the baseline in vital signs Treatment-emergent potentially clinically significant abnormalities (PSCAs) in vital signs, ECG and safety laboratory parameters from Day 1 to EOS. Psychopathological tests: Profile of Mood States 2nd edition questionnaire (POMS-2), Hospital Anxiety and Depression rating scale (HADS), Addiction Research Center Inventory 49 checklist (ARCI-49), Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: 168 hours from dosing

  2. Incidence of treatment-emergent AEs and SAEs as assessed by ECGs

    Evaluation by grade intensity and by evaluating changes from the baseline in ECGs

    Time frame: 168 hours from dosing

  3. Incidence of treatment-emergent AEs and SAEs as assessed by clinical laboratory values

    Evaluation by grade intensity and by evaluating changes from the baseline in clinical laboratory values from blood and urine samples.

    Time frame: 168 hours from dosing

  4. Incidence of treatment-emergent AEs and SAEs as assessed by psychometric tests

    Evaluation by grade intensity and by evaluating changes from the baseline in psychometric tests (Bond and Lader VAS, ARCI, POMS) and C-SSRS test.

    Time frame: 36 hours from dosing

07

Study locations

1 site
  • Hospital del Mar Medical Research Institute (IMIM) Neurosciences Research Program
    Barcelona, 08003, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jun 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Dec 28, 2021
StartActual
Oct 1, 2021
Primary completionActual
Jun 28, 2022
CompletionActual
Jun 28, 2022
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05170737
Lead sponsor
Aelis Farma
Collaborators
European Commission
Responsible party
Sponsor
First posted
Dec 28, 2021
Start date
Oct 1, 2021
Primary completion
Jun 28, 2022
Completion
Jun 28, 2022
Last update
Feb 1, 2024

Study contacts

Rafael de la Torre Fornel, PhD
principal investigator · IMIM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AEF0217

Start the discussion